Page 8 - System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

U.S. now open for enrollmentof rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ --Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollmentat Vanderbilt University Medical Center in Nashville, Tennessee. "Vanderbilt Univers...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ --Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022. Multiple System Atrophy (MSA) is a progressive neurodegenerative disease that presents w...

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and AustraliaApproval of Investigational New Drug a...

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...